Small UK biotech touts long-term da­ta for he­mo­phil­ia B gene ther­a­py as it at­tempts a come­back

As it con­tin­ues push­ing its he­mo­phil­ia B gene ther­a­py to­ward the FDA, small biotech Free­line Ther­a­peu­tics is hop­ing new long-term da­ta will boost its case …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER